Last reviewed · How we verify
Losartan and hydrochlorothiazide — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Losartan and hydrochlorothiazide (Losartan and hydrochlorothiazide) — University of Cambridge.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Losartan and hydrochlorothiazide TARGET | Losartan and hydrochlorothiazide | University of Cambridge | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Losartan and hydrochlorothiazide CI watch — RSS
- Losartan and hydrochlorothiazide CI watch — Atom
- Losartan and hydrochlorothiazide CI watch — JSON
- Losartan and hydrochlorothiazide alone — RSS
Cite this brief
Drug Landscape (2026). Losartan and hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-and-hydrochlorothiazide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab